Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 186

1.

Side-population cells in luminal-type breast cancer have tumour-initiating cell properties, and are regulated by HER2 expression and signalling.

Nakanishi T, Chumsri S, Khakpour N, Brodie AH, Leyland-Jones B, Hamburger AW, Ross DD, Burger AM.

Br J Cancer. 2010 Mar 2;102(5):815-26. doi: 10.1038/sj.bjc.6605553. Epub 2010 Feb 9.

2.

The importance of HER2 signaling in the tumor-initiating cell population in aromatase inhibitor-resistant breast cancer.

Gilani RA, Kazi AA, Shah P, Schech AJ, Chumsri S, Sabnis G, Jaiswal AK, Brodie AH.

Breast Cancer Res Treat. 2012 Oct;135(3):681-92. doi: 10.1007/s10549-012-2148-8. Epub 2012 Aug 10.

PMID:
22878889
3.

Up-regulation of breast cancer resistance protein plays a role in HER2-mediated chemoresistance through PI3K/Akt and nuclear factor-kappa B signaling pathways in MCF7 breast cancer cells.

Zhang W, Ding W, Chen Y, Feng M, Ouyang Y, Yu Y, He Z.

Acta Biochim Biophys Sin (Shanghai). 2011 Aug;43(8):647-53. doi: 10.1093/abbs/gmr050. Epub 2011 Jun 28.

PMID:
21712253
4.

Immunoselection of breast and ovarian cancer cells with trastuzumab and natural killer cells: selective escape of CD44high/CD24low/HER2low breast cancer stem cells.

Reim F, Dombrowski Y, Ritter C, Buttmann M, Häusler S, Ossadnik M, Krockenberger M, Beier D, Beier CP, Dietl J, Becker JC, Hönig A, Wischhusen J.

Cancer Res. 2009 Oct 15;69(20):8058-66. doi: 10.1158/0008-5472.CAN-09-0834. Epub 2009 Oct 13.

5.

Seventeen-gene signature from enriched Her2/Neu mammary tumor-initiating cells predicts clinical outcome for human HER2+:ERα- breast cancer.

Liu JC, Voisin V, Bader GD, Deng T, Pusztai L, Symmans WF, Esteva FJ, Egan SE, Zacksenhaus E.

Proc Natl Acad Sci U S A. 2012 Apr 10;109(15):5832-7. doi: 10.1073/pnas.1201105109. Epub 2012 Mar 28.

6.

Pathway-focused proteomic signatures in HER2-overexpressing breast cancer with a basal-like phenotype: new insights into de novo resistance to trastuzumab (Herceptin).

Oliveras-Ferraros C, Vazquez-Martin A, Martin-Castilló B, Pérez-Martínez MC, Cufí S, Del Barco S, Bernado L, Brunet J, López-Bonet E, Menendez JA.

Int J Oncol. 2010 Sep;37(3):669-78.

PMID:
20664936
7.

HER2-positive breast cancer cells resistant to trastuzumab and lapatinib lose reliance upon HER2 and are sensitive to the multitargeted kinase inhibitor sorafenib.

Valabrega G, Capellero S, Cavalloni G, Zaccarello G, Petrelli A, Migliardi G, Milani A, Peraldo-Neia C, Gammaitoni L, Sapino A, Pecchioni C, Moggio A, Giordano S, Aglietta M, Montemurro F.

Breast Cancer Res Treat. 2011 Nov;130(1):29-40. doi: 10.1007/s10549-010-1281-5. Epub 2010 Dec 9.

PMID:
21153051
8.

HER2 regulates the mammary stem/progenitor cell population driving tumorigenesis and invasion.

Korkaya H, Paulson A, Iovino F, Wicha MS.

Oncogene. 2008 Oct 16;27(47):6120-30. doi: 10.1038/onc.2008.207. Epub 2008 Jun 30.

9.

Overcoming trastuzumab resistance in HER2-overexpressing breast cancer cells by using a novel celecoxib-derived phosphoinositide-dependent kinase-1 inhibitor.

Tseng PH, Wang YC, Weng SC, Weng JR, Chen CS, Brueggemeier RW, Shapiro CL, Chen CY, Dunn SE, Pollak M, Chen CS.

Mol Pharmacol. 2006 Nov;70(5):1534-41. Epub 2006 Aug 3.

10.

Nonhypoxic regulation and role of hypoxia-inducible factor 1 in aromatase inhibitor resistant breast cancer.

Kazi AA, Gilani RA, Schech AJ, Chumsri S, Sabnis G, Shah P, Goloubeva O, Kronsberg S, Brodie AH.

Breast Cancer Res. 2014 Jan 29;16(1):R15. doi: 10.1186/bcr3609.

12.

Substance P autocrine signaling contributes to persistent HER2 activation that drives malignant progression and drug resistance in breast cancer.

Garcia-Recio S, Fuster G, Fernandez-Nogueira P, Pastor-Arroyo EM, Park SY, Mayordomo C, Ametller E, Mancino M, Gonzalez-Farre X, Russnes HG, Engel P, Costamagna D, Fernandez PL, Gascón P, Almendro V.

Cancer Res. 2013 Nov 1;73(21):6424-34. doi: 10.1158/0008-5472.CAN-12-4573. Epub 2013 Sep 12.

13.

ABCG2 inhibitor YHO-13351 sensitizes cancer stem/initiating-like side population cells to irinotecan.

Shishido Y, Ueno S, Yamazaki R, Nagaoka M, Matsuzaki T.

Anticancer Res. 2013 Apr;33(4):1379-86.

PMID:
23564776
15.

STAT3 activation in HER2-overexpressing breast cancer promotes epithelial-mesenchymal transition and cancer stem cell traits.

Chung SS, Giehl N, Wu Y, Vadgama JV.

Int J Oncol. 2014 Feb;44(2):403-11. doi: 10.3892/ijo.2013.2195. Epub 2013 Nov 29.

16.

Identification of a distinct side population of cancer cells in the Cal-51 human breast carcinoma cell line.

Christgen M, Ballmaier M, Bruchhardt H, von Wasielewski R, Kreipe H, Lehmann U.

Mol Cell Biochem. 2007 Dec;306(1-2):201-12. Epub 2007 Jul 28.

PMID:
17660947
17.
18.

The interplay of HER2/HER3/PI3K and EGFR/HER2/PLC-γ1 signalling in breast cancer cell migration and dissemination.

Balz LM, Bartkowiak K, Andreas A, Pantel K, Niggemann B, Zänker KS, Brandt BH, Dittmar T.

J Pathol. 2012 Jun;227(2):234-44. doi: 10.1002/path.3991. Epub 2012 Mar 21. Erratum in: J Pathol. 2013 May;230(1):e1.

PMID:
22262199
19.
20.

Antitumor effect of the mTOR inhibitor everolimus in combination with trastuzumab on human breast cancer stem cells in vitro and in vivo.

Zhu Y, Zhang X, Liu Y, Zhang S, Liu J, Ma Y, Zhang J.

Tumour Biol. 2012 Oct;33(5):1349-62. doi: 10.1007/s13277-012-0383-6. Epub 2012 Apr 11.

PMID:
22492237
Items per page

Supplemental Content

Write to the Help Desk